Cost-Minimisation Analysis of Sucroferric Oxhydroxide and Sevelamer Carbonate in Patients on Dialysis With Secondary Hyperparathyroidism in Six European Countries

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.1001
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Risk Factors for Severe Hypocalcemia After Parathyroidectomy in Dialysis Patients With Secondary Hyperparathyroidism

Scientific Reports
Multidisciplinary
2018English

Evocalcet, a New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism

Therapeutic Apheresis and Dialysis
HematologyNephrology
2019English

Evaluation of the Association of WNT Signaling With Coronary Artery Calcification in Patients on Dialysis With Severe Secondary Hyperparathyroidism

BMC Nephrology
Nephrology
2019English

Cost Analysis of Hemodialysis and Peritoneal Dialysis Access in Incident Dialysis Patients

Peritoneal Dialysis International
MedicineNephrology
2013English

Can We Predict Who Will Develop Postoperative Hyperkalaemia After Parathyroidectomy in Dialysis Patients With Secondary Hyperparathyroidism?

BMC Nephrology
Nephrology
2019English

Acute Bilateral Knee Pain in a Dialysis Patient With Severe Secondary Hyperparathyroidism

Kidney360
2020English

Puk19 - Cost-Utility of Sucroferric Oxyhydroxide for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients Undergoing Dialysis in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Studies on the Small Thyroid Carcinoma in the Dialysis Patients With Hyperparathyroidism

Folia Endocrinologica Japonica
1986English

Costs and Cost-Minimisation Analysis.

BMJ
1993English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy